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Process
In the past, each manuscript submitted 
to the JEM was assigned—by different 
scientific editors in the JEM office during 
different weeks—to one of our 12 aca-
demic  editors.  This  primary  academic 
editor would send the manuscript and 
their opinion of it to a secondary aca-
demic editor, who would then send it, 
along with their opinion, either back to 
the JEM office or to a tertiary academic 
editor for a third opinion.
As of January 2010, all newly sub-
mitted  manuscripts  are  first  read  and 
discussed in the JEM office by an ex-
panding  team  of  full-time  scientific 
editors.  Each  manuscript  is  then  sent, 
together  with  the  scientific  editor 
opinion  and  any  related  manuscripts, 
to one or two academic editors. This 
new  process  should  expedite  the  ini-
tial review process and ensure that re-
lated  manuscripts—which  often  focus   
on highly competitive topics—are han-
dled consistently.
Also  relevant  to  manuscripts  on 
competitive topics: as of March 2010, 
the JEM has the ability to expedite—at 
the  discretion  of  the  editors—online 
publication of accepted papers.
Regardless  of  whether  it  is  true, 
the notion persists that JEM academic 
editors have an easier time than outside 
scientists  publishing  their  manuscripts 
in the JEM. To help dispel this notion 
and make the process of assessing man-
uscripts  from  academic  editors  more 
transparent, as of April 2010, all manu-
scripts submitted to JEM by academic 
editors are handled by one of three des-
ignated outside monitoring editors. In 
selecting monitoring editors, we sought 
outstanding  scientists  who  have  dem-
onstrated a consistent ability to provide 
stellar,  decisive  reviews  of  papers  in   
diverse fields. We are thrilled that our 
first  choices—Jason  Cyster,  Marco 
Colonna,  and  Steve  Hedrick—agreed 
to fill these positions.
Scope
Although stem cell biology, cancer bi-
ology,  and  neurobiology  have  always 
been  within  the  scope  of  the  JEM,   
few  scientists  in  these  rapidly  grow-
ing  fields  regularly  read  the  JEM  or 
submit their work to the journal. This 
is  perhaps  not  a  surprise,  as  each  of 
the  JEM  academic  editors  is  known 
first and foremost as an elite immu-
nologist,  microbiologist,  or  vascu-
lar  biologist.  For  this  reason,  in April 
2010,  the  JEM  welcomed  Andreas 
Trumpp of the Heidelberg Institute for   
Stem  Cell  Technology  and  Exper-
imental  Medicine  (HI-STEM)  and   
the Deutsches Krebsforschungszentrum 
(DKFZ)  Division  of  Stem  Cells  and 
Cancer, a scientist with expertise span-
ning  cancer  and  stem  cell  biology,   
as  a  new  academic  editor. We  also   
invited  Paul  Patterson,  Jim  Malter,   
Sean  Morrison,  Lou  Staudt,  and 
Benjamin Neel to join our roster of 
Advisory Editors.
In addition, to communicate JEM’s 
interest  in  these  fields,  JEM  scien-
tific editors are traveling to relevant 
conferences  and  institutes. As  a  start, 
we  attended  the  Keystone  Stem  Cell 
Differentiation  and  Dedifferentiation 
meeting  in  February,  met  with  stem 
cell and cancer biologists in Boston in 
March,  will  visit  laboratories  in  New 
York in April and London in June, and 
will  attend  the  Cold  Spring  Harbor 
meeting on Mechanisms and Models of 
Cancer in August.
You’ll also note that we’ve invited 
prominent  scientists  in  these  fields  to 
write  commentaries  on  relevant  JEM 
papers. Ross Levine and Omar Abdel-
Wahab  wrote  “Metabolism  and  the 
leukemic  stem  cell”  in  our  April  12 
issue, and you will see additional pieces 
in May and June.
Content
Starting  this  summer,  JEM  will  also 
publish Reviews and Perspectives. These   
pieces will be commissioned on broad 
topics that would benefit from an ex-
pert effort to tie together a series of 
recent but separate observations with a 
unique “big picture” viewpoint.
Lastly, we have refocused our no-
tion  of  what  a  JEM  Brief  Definitive 
Report  should  be.  Rather  than  sim-
ply a shorter version of an Article, the 
BDR format will be reserved for stud-
ies presenting very surprising findings 
with  the  potential  to  spark  new  av-
enues of research, studies that provide 
definitive  answers  to  persistent  open 
questions  or  settle  controversies  of 
broad interest, or studies that present 
concise conceptual advances in rapidly 
moving fields.
Please feel free to send feedback 
on these changes and/or suggestions 
for additional improvements to my-
self (cborowski@rockefeller.edu) or to 
our  Senior  Editor  Heather  van  Epps 
(hvanepps@rockefeller.edu). I hope to 
see you at a conference or laboratory 
visit in the near future.
Optimizing the JEM
Christine Borowski
Executive Editor, The Journal of Experimental Medicine
Published since 1896, the Journal of Experimental Medicine was long ago 
established as a reliable source of high-impact findings relevant to human 
disease. Five months ago, I joined the JEM as Executive Editor, with the aim 
of making this strong journal even stronger. This editorial describes recent 
and ongoing changes to the JEM’s process, scope, and content.
CORRESPONDENCE  
Christine Borowski: cborowski@rockefeller.edu
© 2010 Borowski  This article is distributed under the terms of an 
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license 
for the first six months after the publication date (see http://www 
.rupress.org/terms). After six months it is available under a Creative 
Commons License (Attribution–Noncommercial–Share Alike 3.0 Un-
ported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e